An AUSTRALIAN Public Assessment Report (AusPAR) has been posted by the Therapeutic Goods Administration for Roche's idiopathic pulmonary fibrosis treatment Esbriet (pirfenidone).
Go to www.tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 31 Aug 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Aug 16
